Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial
Gerd R Burmester,Yong Lin,Rahul Patel,Janet van Adelsberg,E.K. Mangan,Neil M.H. Graham,Hubert van Hoogstraten,Deborah Bauer,Juan Ignacio Vargas,Eun Bong Lee +9 more
Reads0
Chats0
TLDR
Sarilumabmonotherapy demonstrated superiority to adalimumab monotherapy by improving the signs and symptoms and physical functions in patients with RA who were unable to continue MTX treatment.Abstract:
Objectives To compare efficacy and safety of sarilumab monotherapy with adalimumab monotherapy in patients with active rheumatoid arthritis (RA) who should not continue treatment with methotrexate (MTX) due to intolerance or inadequate response. Methods MONARCH was a randomised, active-controlled, double-blind, double-dummy, phase III superiority trial. Patients received sarilumab (200 mg every 2 weeks (q2w)) or adalimumab (40 mg q2w) monotherapy for 24 weeks. The primary end point was change from baseline in 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) at week 24. Results Sarilumab was superior to adalimumab in the primary end point of change from baseline in DAS28-ESR (−3.28 vs −2.20; p Conclusions Sarilumab monotherapy demonstrated superiority to adalimumab monotherapy by improving the signs and symptoms and physical functions in patients with RA who were unable to continue MTX treatment. The safety profiles of both therapies were consistent with anticipated class effects. Trial registration number NCT02332590.read more
Citations
More filters
Journal ArticleDOI
Dynamics of patient reported outcomes during the use various biological disease-modifying antirheumatic drugs for rheumatoid arthritis
A. E. Karateev,A M Lila,Taras S. Panevin,A. S. Potapova,A. S. Semashko,A. O. Bobkova,V. N. Amirjanova,Evgeniy Zotkin +7 more
TL;DR: The use of bDMARDs in combination with methotrexate (MTX) provides a reduction in PGA and pain by 50-60%, functional disorders according to HAQ and fatigue according to FACIT-F (Functional Assessment of Chronic Illness Therapy – Fatigue) – by 15-30%.
Journal ArticleDOI
Clinical remission of rheumatoid arthritis in a multicenter real-world study in Asia-Pacific region.
Xing Sun,Ru Li,Yueming Cai,Adeeba Al-Herz,Manjari Lahiri,Minhaj Rahim Choudhury,Rudy Hidayat,Bagus Putu Putra Suryana,Yuko Kaneko,Keishi Fujio,Nguyen Van Hung,Sapan Pandya,Leong Khai Pang,Wanruchada Katchamart,Keshav Raj Sigdel,Buddhi Paudyal,Pongthorn Narongroeknawin,Parawee Chevaisrakul,Feng Sun,Yu Lu,Carmen Ho,Swan Sim Yeap,Zhanguo Li +22 more
TL;DR: In this article, a cross-sectional multicentric study was conducted to evaluate the clinical remission status and the related factors in RA patients in the Asia-Pacific region, where patients receiving standard care were enrolled consecutively from 17 sites in 11 countries from APLAR RA SIG group and data were collected on-site by rheumatologists with a standardized case-report form.
Journal ArticleDOI
Correction to: Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data.
Markus Rehberg,Clemens Giegerich,A. Praestgaard,Hubert van Hoogstraten,Melitza Iglesias-Rodriguez,Jeffrey R. Curtis,Jacques-Eric Gottenberg,Andreas Schwarting,Santos Castañeda,Andrea Rubbert-Roth,Ernest Choy +10 more
TL;DR: In this article, a decision tree model was used to predict the response to sarilumab and discriminate between responses to adalimumab, with a focus on clinically feasible blood biomarkers.
Journal ArticleDOI
Population Pharmacokinetic–Pharmacodynamic Relationships of Sarilumab Using Disease Activity Score 28-Joint C-Reactive Protein and Absolute Neutrophil Counts in Patients with Rheumatoid Arthritis
TL;DR: Data from phase I–III studies contribute to the totality of evidence that supports a sarilumab subcutaneous starting dose of 200 mg every 2 weeks, with a subsequent reduction to 150 mgevery 2-weeks in the event of laboratory abnormalities such as neutropenia.
Journal ArticleDOI
The balance between Treg and TH17 cells: CD11b and interleukin‐6
TL;DR: Although WT C57BL/6 mice are resistant to collagen‐induced arthritis, mice with a homozygous deletion of CD11b on the same genetic background are fully susceptible in this important animal model of rheumatoid arthritis.
References
More filters
Journal ArticleDOI
2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.
Daniel Aletaha,Tuhina Neogi,Alan J. Silman,Julia Funovits,David T. Felson,Clifton O. Bingham,Neal S. Birnbaum,Gerd Burmester,Vivian P. Bykerk,Marc D. Cohen,Bernard Combe,Karen H. Costenbader,Maxime Dougados,Paul Emery,Gianfranco Ferraccioli,Johanna M. W. Hazes,Kathryn Hobbs,Tom W J Huizinga,Arthur Kavanaugh,Jonathan Kay,Tore K Kvien,Timothy J. Laing,Philip J. Mease,Henri A Ménard,Larry W. Moreland,Raymond L. Naden,Theodore Pincus,Josef S Smolen,Ewa Stanislawska-Biernat,Deborah P M Symmons,Paul P. Tak,Katherine S. Upchurch,Jiří Vencovský,Frederick Wolfe,Gillian A. Hawker +34 more
TL;DR: This new classification system redefines the current paradigm of RA by focusing on features at earlier stages of disease that are associated with persistent and/or erosive disease, rather than defining the disease by its late-stage features.
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
Josef S Smolen,Robert Landewé,Ferdinand C. Breedveld,Maxime Dougados,Paul Emery,Cécile Gaujoux-Viala,Simone L Gorter,Rachel Knevel,Jackie L Nam,Monika Schoels,Daniel Aletaha,Maya H Buch,Laure Gossec,T.W.J. Huizinga,Johannes W. J. Bijlsma,G.-R. Burmester,B. Combe,Maurizio Cutolo,Cem Gabay,Juan J. Gomez-Reino,Marios Kouloumas,Tore K Kvien,E. Martin-Mola,Iain B. McInnes,Karel Pavelka,P.L.C.M. van Riel,M. Scholte,David Scott,T. Sokka,Guido Valesini,R. van Vollenhoven,Kevin L. Winthrop,John B. Wong,A. Zink,D. van der Heijde +34 more
TL;DR: Recommendations are intended to inform rheumatologists, patients and other stakeholders about a European consensus on the management of RA with DMARDs and GCs as well as strategies to reach optimal outcomes of RA based on evidence and expert opinion.
Journal ArticleDOI
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
Peter E. Lipsky,D. van der Heijde,E W St Clair,Daniel E. Furst,F. C. Breedveld,J. R. Kalden,Josef S. Smolen,M Weisman,Paul Emery,Marc Feldmann,Gregory Harriman,Ravinder Nath Maini +11 more
TL;DR: In patients with persistently active rheumatoid arthritis despite methotrexate therapy, repeated doses of infliximab in combination with methotRexate provided clinical benefit and halted the progression of joint damage.
Journal ArticleDOI
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Jasvinder A. Singh,Kenneth G. Saag,S. Louis Bridges,Elie A. Akl,Raveendhara R. Bannuru,Matthew C. Sullivan,Elizaveta E. Vaysbrot,Christine McNaughton,Mikala C. Osani,Robert H. Shmerling,Jeffrey R. Curtis,Daniel E. Furst,Deborah Parks,Arthur Kavanaugh,James R. O'Dell,Charles H. King,Amye Leong,Eric L. Matteson,John T. Schousboe,Barbara E. Drevlow,Seth Ginsberg,James Grober,E. William St. Clair,Elizabeth A. Tindall,Amy S. Miller,Timothy E. McAlindon +25 more
TL;DR: To develop a new evidence‐based, pharmacologic treatment guideline for rheumatoid arthritis (RA), a large number of patients with RA are referred to a single clinic for treatment with these medications.
Journal ArticleDOI
A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis
Joan M. Bathon,Richard J. Martin,Roy Fleischmann,John Tesser,Michael Schiff,Edward C. Keystone,Mark C. Genovese,Mary Chester M. Wasko,Larry W. Moreland,Arthur L. Weaver,Joseph A. Markenson,Barbara K. Finck +11 more
TL;DR: Subcutaneous [corrected] etanercept acted more rapidly to decrease symptoms and slow joint damage in patients with early active rheumatoid arthritis.
Related Papers (5)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Josef S Smolen,Robert Landewé,Ferdinand C. Breedveld,Maya H Buch,Maya H Buch,Gerd R Burmester,Maxime Dougados,Paul Emery,Paul Emery,Cécile Gaujoux-Viala,Laure Gossec,Jackie L Nam,Jackie L Nam,Sofia Ramiro,Kevin L. Winthrop,Maarten de Wit,Daniel Aletaha,Neil Betteridge,Johannes W. J. Bijlsma,Maarten Boers,Frank Buttgereit,Bernard Combe,Maurizio Cutolo,Nemanja Damjanov,Johanna M. W. Hazes,Marios Kouloumas,Tore K Kvien,Xavier Mariette,Karel Pavelka,Piet L. C. M. van Riel,Andrea Rubbert-Roth,Marieke Scholte-Voshaar,David Scott,T. Sokka-Isler,John B. Wong,Désirée van der Heijde +35 more
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Jasvinder A. Singh,Kenneth G. Saag,S. Louis Bridges,Elie A. Akl,Raveendhara R. Bannuru,Matthew C. Sullivan,Elizaveta E. Vaysbrot,Christine McNaughton,Mikala C. Osani,Robert H. Shmerling,Jeffrey R. Curtis,Daniel E. Furst,Deborah Parks,Arthur Kavanaugh,James R. O'Dell,Charles H. King,Amye Leong,Eric L. Matteson,John T. Schousboe,Barbara E. Drevlow,Seth Ginsberg,James Grober,E. William St. Clair,Elizabeth A. Tindall,Amy S. Miller,Timothy E. McAlindon +25 more